Compile Data Set for Download or QSAR
Report error Found 487 Enz. Inhib. hit(s) with Target = 'Protein SSX2/Protein SSXT'
TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM565259(US11414416, Compound D1 | US11560381, Compound D1)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM565262(US11414416, Compound D3 | US11560381, Compound D3 ...)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM565265(US11414416, Compound D6 | US11560381, Compound D6)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM565268(US11414416, Compound D9 | US11560381, Compound D9)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM565269(US11414416, Compound D10 | US11560381, Compound D1...)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM565270(US11414416, Compound D11 | US11560381, Compound D1...)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM565271(US11414416, Compound D12 | US11560381, Compound D1...)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM565272(US11414416, Compound D13 | US11560381, Compound D1...)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM565273(US11414416, Compound D14 | US11560381, Compound D1...)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM565274(US11414416, Compound D15 | US11560381, Compound D1...)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM590341(US11560381, Compound D16)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM565272(US11414416, Compound D13 | US11560381, Compound D1...)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM590343((2S)-1-[[2,6-dimethoxy-4-(2-methyl-1-oxo-2,7-napht...)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM590344((2S)-1-[[2,6-dimethoxy-4-(2-methyl-1-oxo-2,7-napht...)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM590345(6-[[2,6-dimethoxy-4-(2-methyl-1-oxo-1,2,4a,8a-tetr...)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM565276(US11414416, Compound D23 | US11560381, Compound D2...)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM565284(US11414416, Compound D33 | US11560381, Compound D3...)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM565285(US11414416, Compound D34 | US11560381, Compound D3...)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM565286(US11414416, Compound D35 | US11560381, Compound D3...)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM565288(US11414416, Compound D37 | US11560381, Compound D3...)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM565289(US11414416, Compound D38 | US11560381, Compound D3...)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM565290(US11414416, Compound D39 | US11560381, Compound D3...)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM565291(US11414416, Compound D40 | US11560381, Compound D4...)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM590350(US11560381, Compound D42)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM590352(US11560381, Compound D44)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM590353(1-[[2,6-dimethoxy-4-(2-methyl-1-oxo-2,7-naphthyrid...)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM590354(US11560381, Compound D46)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM590355(US11560381, Compound D47)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM590358(5-(4-(9-(2,6-dimethoxy-4-(2-methyl-1-oxo-1,2-dihyd...)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM590359(BDBM590369 | US11560381, Compound D51)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM565293(US11414416, Compound D52 | US11560381, Compound D5...)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM565294(US11414416, Compound D53 | US11560381, Compound D5...)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM565297(US11414416, Compound D56 | US11560381, Compound D5...)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM565298(US11414416, Compound D57 | US11560381, Compound D5...)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM565299(US11414416, Compound D58 | US11560381, Compound D5...)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM565300(US11414416, Compound D59 | US11560381, Compound D5...)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM565301(US11414416, Compound D60 | US11560381, Compound D6...)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM565308(US11414416, Compound D67 | US11560381, Compound D6...)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM565310(US11414416, Compound D69 | US11560381, Compound D6...)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM565312(US11414416, Compound D71 | US11560381, Compound D7...)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM565313(US11414416, Compound D72 | US11560381, Compound D7...)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM565314(US11414416, Compound D73 | US11560381, Compound D7...)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM590360(US11560381, Compound D75)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM590361(BDBM590371 | US11560381, Compound D76)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM590365(US11560381, Compound D80 | BDBM590375)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM590366(US11560381, Compound D81 | BDBM590376)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM590252(US11560381, Compound D89)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM565332(US11414416, Compound D100 | US11560381, Compound D...)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM565341(US11414416, Compound D108 | US11560381, Compound D...)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetProtein SSX2/Protein SSXT(Human)
Foghorn Therapeutics

US Patent
LigandPNGBDBM565346(US11414416, Compound D113 | US11560381, Compound D...)
Affinity DataIC50: 10nMAssay Description:This example demonstrates the ability of the compounds of the disclosure to degrade a Nano luciferase-BRO9 fusion protein in a cell-based degradation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

Displayed 1 to 50 (of 487 total ) | Next | Last >>
Jump to: